<DOC>
	<DOCNO>NCT00576901</DOCNO>
	<brief_summary>This single arm study ass efficacy safety combination first-line treatment docetaxel + Xeloda + Avastin patient inflammatory locally advanced breast cancer . Patients receive 3-weekly cycle Avastin ( 15mg/kg i.v . day 1 cycle ) , docetaxel ( 75mg/m2 i.v . day 1 cycle , Avastin ) Xeloda ( 2000mg/m2 p.o . day 1-15 cycle ) . Four cycle chemotherapy plan , plus optional additional two cycle ; chemotherapy patient assess surgery . The anticipated time study treatment 3-12 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Combination With Xeloda ( Capecitabine ) Docetaxel Patients With Inflammatory Locally Advanced Breast Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>female patient , &gt; =18 year age ; HER2negative , locally advanced ( stage II III ) inflammatory cancer breast ; ECOG performance status 01. metastatic disease ( stage IV ) ; previous treatment breast cancer ; evidence CNS metastasis ; current recent ( within 10 day first dose Avastin ) use aspirin ( &gt; 325mg/day ) NSAIDs full dose anticoagulant therapeutic purpose ; clinically significant cardiovascular disease .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>